The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial.

ABSTRACT:

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with dysbiosis of the gut microbiota. We evaluated the effect of next generation probiotics (Lactobacillus delbrueckii subsp. Lactis [LL001], L. helveticus [LH001], and Pediococcus pentosaceus KID7 [PPKID7]) on liver function parameters and stool microbiome in patients with MASLD.

Methods

We conducted a double-blind parallel trial of 110 patients diagnosed with MASLD. Participants were randomly assigned to four groups given three probiotics (3 capsules [9 × 10⁹ CFU]/day, n = 85) or placebo (n = 25) alongside sylimarin for 8 weeks. Clinical characteristics, serum samples, and stool samples for 16 S rRNA gene sequencing were collected at the start and end point of the study. Th

SUBMITTER: Won SM 

PROVIDER: S-EPMC12801763 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature